A white paper entitled ‘Abuse Deterrence for the Pharmaceutical Market?’ has been published by materials technology company Lucideon.
Written by healthcare product manager Aia Malik and healthcare business manager Gemma Budd, the paper discusses the requirements for abuse deterrent solutions for pharmaceutical products and what technologies are being developed to meet this. The authors explore the current crisis surrounding prescription drug abuse and the available technologies that are currently helping to combat this issue. They also look at the potential solutions of future technologies.
Lucideon’s experts have developed the new inorganic controlled-release technology (iCRT) drug delivery platform, offering a range of improvements on existing controlled-release systems in terms of drug abuse deterrence.
Malik said: “Prescription drug abuse has become a big problem globally with South Asia and the US seeing the worst cases.
“Prescription drug abuse can be directly linked to an increase in deaths, financial burden and strain on healthcare services. The development of drug delivery platforms that deter abuse is important to combat this and ensure the availability of prescription drugs for those who really need them. In addition to having a range of deterrent properties, iCRT is highly versatile allowing for tailored products to be designed to suit each individual application.”
To find out more about Lucideon’s abuse deterrent technologies services visit www.lucideon.com/icrt-deter.